Point72 Asset Management L.P. Sells 67,086 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Point72 Asset Management L.P. decreased its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 2.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,778,267 shares of the company's stock after selling 67,086 shares during the quarter. Point72 Asset Management L.P. owned approximately 3.25% of Syndax Pharmaceuticals worth $53,482,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. Sofinnova Investments Inc. grew its stake in shares of Syndax Pharmaceuticals by 33.9% during the second quarter. Sofinnova Investments Inc. now owns 2,153,669 shares of the company's stock valued at $44,215,000 after purchasing an additional 545,129 shares during the last quarter. First Turn Management LLC lifted its holdings in Syndax Pharmaceuticals by 85.4% during the 3rd quarter. First Turn Management LLC now owns 1,187,165 shares of the company's stock worth $22,853,000 after buying an additional 546,776 shares in the last quarter. Millennium Management LLC boosted its position in Syndax Pharmaceuticals by 56.3% in the 2nd quarter. Millennium Management LLC now owns 1,065,508 shares of the company's stock valued at $21,875,000 after buying an additional 383,634 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at $15,165,000. Finally, Eventide Asset Management LLC bought a new stake in shares of Syndax Pharmaceuticals during the third quarter worth $15,150,000.

Syndax Pharmaceuticals Stock Performance

SNDX stock traded down $0.12 during mid-day trading on Thursday, hitting $16.80. 1,112,008 shares of the company were exchanged, compared to its average volume of 1,169,302. The firm has a market cap of $1.43 billion, a P/E ratio of -4.63 and a beta of 0.86. Syndax Pharmaceuticals, Inc. has a 1-year low of $15.00 and a 1-year high of $25.34. The firm's 50 day simple moving average is $18.33 and its 200 day simple moving average is $19.69.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, topping analysts' consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same period in the previous year, the company posted ($0.73) earnings per share. On average, equities research analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Citigroup lifted their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, November 19th. StockNews.com downgraded shares of Syndax Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, November 23rd. Barclays increased their price objective on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a report on Thursday, August 15th. The Goldman Sachs Group lifted their target price on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, November 7th. Finally, JPMorgan Chase & Co. upped their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an "overweight" rating in a research report on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Syndax Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $37.64.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).